"10.1371_journal.pone.0100880","plos one","2014-06-30T00:00:00Z","Melissa Dumble; Ming-Chih Crouthamel; Shu-Yun Zhang; Michael Schaber; Dana Levy; Kimberly Robell; Qi Liu; David J Figueroa; Elisabeth A Minthorn; Mark A Seefeld; Meagan B Rouse; Sridhar K Rabindran; Dirk A Heerding; Rakesh Kumar","Oncology R & D, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America; Platform Technology & Science, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America","Conceived and designed the experiments: MD MC SZ MS DL KR QL DJF EAM MAS MBR SKR DAH RK. Performed the experiments: MD MC SZ MS DL KR QL DJF EAM MAS MBR. Analyzed the data: MD MC SZ MS DL KR QL DJF EAM MAS MBR SKR DAH RK. Contributed reagents/materials/analysis tools: MAS MBR. Contributed to the writing of the manuscript: MD MS DAH RK.","Funding for the work was provided by GlaxoSmithKline, the employer of all authors at the time of the study. MD, MAS, MBR, DAH and RK are inventors on the patents describing identification and/or use of compounds described. GSK2110183 and GSK2141795 are compounds in clinical development. GSK1120212 (trametinib) is an approved drug for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Relevant patents are as follows: 1. Seefeld MA, Rouse MB, Heerding DA, Peace S, Yamashita DS, McNulty KC. Inhibitors of Akt activity (Preparation of GSK2110183 and GSK2141795). WO 2008098104 A1 (US2008/053269). 2. Dumble M, Gilmer T, Kumar R, Lebowitz PF, Morris SR, Laquerre S. Combinations (Trametinib and GSK2110183). WO2011038085 A1 (US2010/049952). 3. Dumble M, Gilmer T, Kumar R, Lebowitz PF, Morris SR, Laquerre S. Combinations (Trametinib and GSK2141795). WO2011038082 A1 (US2010/049946). 4. Dumble M, Gilmer T, Kumar R, Laquerre S, Lebowitz PF, Morris SR. Combinations (Dabrafenib and GSK2110183). WO2011044415 A1 (US 2010/051909). 5. Dumble M, Gilmer T, Kumar R, Laquerre S, Lebowitz PF, Morris SR. Combinations (Dabrafenib and GSK2141795). WO2011044414 A1 (US2010/051907). 6. Kumar R. Combination (GSK2110183 and pazopanib). WO2011150044 A1 (US 2011/037881). 7. Kumar R. Combination (GSK2141795 and pazopanib). WO2014066204 A1 (US 2013/065829). 8. Gilmer TM, Kumar R. Combinations (Lapatinib and GSK2110183). WO2011146710 01 (US 2011/037141). 9. Gilmer TM, Kumar R. Combinations (Lapatinib and GSK2141795). WO2014066202 A1 (US 2013/065827). 10. Kumar R. Combination (GSK2110183 and proteasome inhibitors). WO2012097021 (US 2012/020863; US2012/0258933). There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","06","Melissa Dumble","MD",14,TRUE,14,11,14,NA,TRUE,TRUE,FALSE,0,NA,FALSE
